Sangamo Therapeutics, Inc. (LON:0R1D)
London
· Delayed Price · Currency is GBP · Price in USD 0.5436
+0.0037 (0.69%)
At close: Jul 2, 2025
Sangamo Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -79.45 | -97.94 | -257.83 | -192.28 | -178.29 | -121 | Upgrade
|
Depreciation & Amortization | 8.76 | 9.36 | 22.19 | 20.56 | 17.64 | 13.37 | Upgrade
|
Loss (Gain) From Sale of Assets | -1.03 | -1.03 | - | - | - | 0.22 | Upgrade
|
Asset Writedown & Restructuring Costs | 1.17 | 5.52 | 155.01 | - | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | - | -0.27 | -2.33 | -1.24 | 2.84 | -0.83 | Upgrade
|
Stock-Based Compensation | 12.26 | 12.38 | 27.36 | 31.65 | 32.96 | 25.71 | Upgrade
|
Other Operating Activities | 1.73 | 0.33 | -5.22 | - | -6.51 | -0.19 | Upgrade
|
Change in Accounts Receivable | 0.33 | 0.4 | 2.76 | 2.34 | -0.79 | 31.69 | Upgrade
|
Change in Accounts Payable | -5.01 | -14.17 | 5.59 | 13.35 | -7.66 | 10.7 | Upgrade
|
Change in Unearned Revenue | 13.43 | 13.43 | -161.16 | -91.33 | -84.2 | 216.55 | Upgrade
|
Change in Income Taxes | 0.56 | 0.56 | -3.73 | - | - | - | Upgrade
|
Change in Other Net Operating Assets | 2.64 | 4.29 | -7.49 | -6.67 | -9.24 | -6.35 | Upgrade
|
Operating Cash Flow | -44.63 | -67.14 | -224.84 | -223.63 | -233.25 | 169.88 | Upgrade
|
Capital Expenditures | -0.27 | -0.27 | -21.16 | -20.17 | -23.28 | -14.71 | Upgrade
|
Sale of Property, Plant & Equipment | 1.95 | 1.95 | - | - | - | - | Upgrade
|
Cash Acquisitions | - | - | - | - | -0.12 | -0.7 | Upgrade
|
Investment in Securities | - | 35.84 | 174.69 | 79.46 | 271.6 | -256.21 | Upgrade
|
Investing Cash Flow | 1.68 | 37.52 | 153.53 | 59.29 | 248.2 | -271.63 | Upgrade
|
Issuance of Common Stock | 17.12 | 29.28 | 16.04 | 86.76 | 36.12 | 153.87 | Upgrade
|
Repurchase of Common Stock | -2.73 | -0.9 | -1.45 | -2.1 | -3.26 | -0.77 | Upgrade
|
Financing Cash Flow | 14.39 | 28.38 | 14.59 | 84.66 | 32.86 | 153.1 | Upgrade
|
Foreign Exchange Rate Adjustments | -0.1 | -2.05 | 1.48 | 1.25 | -0.26 | -0.45 | Upgrade
|
Net Cash Flow | -28.65 | -3.29 | -55.24 | -78.43 | 47.54 | 50.9 | Upgrade
|
Free Cash Flow | -44.89 | -67.41 | -246 | -243.8 | -256.53 | 155.16 | Upgrade
|
Free Cash Flow Margin | -70.41% | -116.62% | -139.59% | -219.05% | -231.73% | 131.28% | Upgrade
|
Free Cash Flow Per Share | -0.21 | -0.33 | -1.41 | -1.58 | -1.77 | 1.15 | Upgrade
|
Levered Free Cash Flow | -20.65 | -38.09 | -98.11 | -110.51 | -107.24 | 41.35 | Upgrade
|
Unlevered Free Cash Flow | -18.63 | -38.09 | -98.11 | -110.51 | -107.24 | 41.35 | Upgrade
|
Change in Net Working Capital | -11.12 | -1.9 | 55.08 | 16.75 | 19.97 | -97.95 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.